Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimers disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation. PKR is also activated during apoptosis, autophagy, neuroinflammation, and A peptide toxicity, which are prominent features of Alzheimer's Disease (AD). Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases. ProteKt Therapeutics was established in the FutuRx Incubator in December 2015 based on technology from Prof. Kobi Rosenblum's lab (Haifa University) and is now fully owned by Bukwang Pharmaceutical.